Therapeutic options for difficult-to-treat Acinetobacter baumannii infections: a 2020 perspective

References

• Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev. 2008;21:538–582.
   PubMed Web of Science ®Google Scholar
• Giannella M, Bussini L, Pascale R, et al. Prognostic utility of the new definition of difficult-to-treat resistance among patients with gram-negative bloodstream infections. Open Forum Infect Dis. 2019;6:ofz505.
   PubMed Web of Science ®Google Scholar
• Kadri SS, Adjemian J, Lai YL, et al. Difficult-to-treat resistance in gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents. Clin Infect Dis. 2018;67:1803–1814.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Giacobbe DR. Judging the appropriate therapy for carbapenem-resistant Acinetobacter infections. Expert Opin Pharmacother. 2020;21:135–138.
   PubMed Web of Science ®Google Scholar
• Harding CM, Hennon SW, Feldman MF. Uncovering the mechanisms of Acinetobacter baumannii virulence. Nat Rev Microbiol. 2018;16:91–102.
   PubMed Web of Science ®Google Scholar
• FDA Drug Safety Communication. FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new Boxed Warning. [cited 2020 Jun 27]. Available from: https://www.fda.gov/drugs/drugsafety/ucm369580.htm.
   Google Scholar
• Tsuji BT, Pogue JM, Zavascki AP, et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019;39:10–39.
   PubMed Web of Science ®Google Scholar
• Panidis D, Markantonis SL, Boutzouka E, et al. Penetration of gentamicin into the alveolar lining fluid of critically ill patients with ventilator-associated pneumonia. Chest. 2005;128:545–552.
   PubMed Web of Science ®Google Scholar
• Giacobbe DR, Mikulska M, Viscoli C. Recent advances in the pharmacological management of infections due to multidrug-resistant gram-negative bacteria. Expert Rev Clin Pharmacol. 2018;11:1219–1236.
   PubMed Web of Science ®Google Scholar
• Russo A, Bassetti M, Ceccarelli G, et al. Bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii: clinical features, therapy and outcome from a multicenter study. J Infect. 2019;79(2):130–138.
   PubMed Web of Science ®Google Scholar
• Qureshi ZA, Hittle LE, O’Hara JA, et al. Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance. Clin Infect Dis. 2015;60:1295–1303.
   PubMed Web of Science ®Google Scholar
• Giacobbe DR, Di Masi A, Leboffe L, et al. Hypoalbuminemia as a predictor of acute kidney injury during colistin treatment. Sci Rep. 2018;8:11968.
   PubMed Web of Science ®Google Scholar
• De Oliveira DMP, Forde BM, Kidd TJ, et al. Antimicrobial resistance in ESKAPE pathogens. Clin Microbiol Rev. 2020;33:e00181-19.
   Web of Science ®Google Scholar
• Naas T, Oueslati S, Bonnin RA, et al. Beta-lactamase database (BLDB) - structure and function. J Enzyme Inhib Med Chem. 2017;32:917–919.
   PubMed Web of Science ®Google Scholar
• Butler DA, Biagi M, Tan X, et al. Multidrug resistant acinetobacter baumannii: resistance by any other name would still be hard to treat. Curr Infect Dis Rep. 2019;21:46.
   PubMed Web of Science ®Google Scholar
• Tian GB, Adams-Haduch JM, Taracila M, et al. Extended-spectrum AmpC cephalosporinase in Acinetobacter baumannii: ADC-56 confers resistance to cefepime. Antimicrob Agents Chemother. 2011;55:4922–4925.
   PubMed Web of Science ®Google Scholar
• Villalon P, Valdezate S, Medina-Pascual MJ, et al. Epidemiology of the Acinetobacter-derived cephalosporinase, carbapenem-hydrolysing oxacillinase and metallo-beta-lactamase genes, and of common insertion sequences, in epidemic clones of Acinetobacter baumannii from Spain. J Antimicrob Chemother. 2013;68:550–553.
   PubMed Web of Science ®Google Scholar
• Evans BA, Amyes SG. OXA beta-lactamases. Clin Microbiol Rev. 2014;27:241–263.
   PubMed Web of Science ®Google Scholar
• Al-Agamy MH, Jeannot K, El-Mahdy TS, et al. First detection of GES-5 carbapenemase-producing Acinetobacter baumannii isolate. Microb Drug Resist. 2017;23:556–562.
   PubMed Web of Science ®Google Scholar
• Hamidian M, Nigro SJ. Emergence, molecular mechanisms and global spread of carbapenem-resistant Acinetobacter baumannii. Microb Genom. 2019;5:e000306.
   Web of Science ®Google Scholar
• Robledo IE, Aquino EE, Sante MI, et al. Detection of KPC in Acinetobacter spp. in Puerto Rico. Antimicrob Agents Chemother. 2010;54:1354–1357.
   PubMed Web of Science ®Google Scholar
• Yang Y, Xu Q, Li T, et al. OXA-23 is a prevalent mechanism contributing to sulbactam resistance in diverse acinetobacter baumannii clinical strains. Antimicrob Agents Chemother. 2019;63:e01676-18.
   Web of Science ®Google Scholar
• Hujer KM, Hujer AM, Endimiani A, et al. Rapid determination of quinolone resistance in Acinetobacter spp. J Clin Microbiol. 2009;47:1436–1442.
   PubMed Web of Science ®Google Scholar
• Karlowsky JA, Draghi DC, Jones ME, et al. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob Agents Chemother. 2003;47:1681–1688.
   PubMed Web of Science ®Google Scholar
• Chopra S, Galande A. A fluoroquinolone-resistant Acinetobacter baumannii without the quinolone resistance-determining region mutations. J Antimicrob Chemother. 2011;66:2668–2670.
   PubMed Web of Science ®Google Scholar
• Coyne S, Rosenfeld N, Lambert T, et al. Overexpression of resistance-nodulation-cell division pump AdeFGH confers multidrug resistance in Acinetobacter baumannii. Antimicrob Agents Chemother. 2010;54:4389–4393.
   PubMed Web of Science ®Google Scholar
• Bulens SN, Yi SH, Walters MS, et al. Carbapenem-nonsusceptible acinetobacter baumannii, 8 US metropolitan areas, 2012-2015. Emerg Infect Dis. 2018;24:727–734.
   PubMed Web of Science ®Google Scholar
• Magnet S, Courvalin P, Lambert T. Resistance-nodulation-cell division-type efflux pump involved in aminoglycoside resistance in Acinetobacter baumannii strain BM4454. Antimicrob Agents Chemother. 2001;45:3375–3380.
   PubMed Web of Science ®Google Scholar
• Shrestha S, Tada T, Shrestha B, et al. Emergence of aminoglycoside resistance due to armA methylase in multi-drug resistant acinetobacter baumannii isolates in a University hospital in Nepal. J Nepal Health Res Counc. 2016;14:72–76.
   PubMedGoogle Scholar
• Akers KS, Mende K, Yun HC, et al. Tetracycline susceptibility testing and resistance genes in isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus complex from a U.S. military hospital. Antimicrob Agents Chemother. 2009;53:2693–2695.
   PubMed Web of Science ®Google Scholar
• Arroyo LA, Herrera CM, Fernandez L, et al. The pmrCAB operon mediates polymyxin resistance in Acinetobacter baumannii ATCC 17978 and clinical isolates through phosphoethanolamine modification of lipid A. Antimicrob Agents Chemother. 2011;55:3743–3751.
   PubMed Web of Science ®Google Scholar
• Beceiro A, Llobet E, Aranda J, et al. Phosphoethanolamine modification of lipid A in colistin-resistant variants of Acinetobacter baumannii mediated by the pmrAB two-component regulatory system. Antimicrob Agents Chemother. 2011;55:3370–3379.
   PubMed Web of Science ®Google Scholar
• Chin CY, Gregg KA, Napier BA, et al. A PmrB-Regulated deacetylase required for lipid a modification and polymyxin resistance in Acinetobacter baumannii. Antimicrob Agents Chemother. 2015;59:7911–7914.
   PubMed Web of Science ®Google Scholar
• Moffatt JH, Harper M, Harrison P, et al. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob Agents Chemother. 2010;54:4971–4977.
   PubMed Web of Science ®Google Scholar
• Martins-Sorenson N, Snesrud E, Xavier DE, et al. A novel plasmid-encoded mcr-4.3 gene in a colistin-resistant Acinetobacter baumannii clinical strain. J Antimicrob Chemother. 2020;75:60–64.
   PubMed Web of Science ®Google Scholar
• Giacobbe DR, Saffioti C, Losito AR, et al. Use of colistin in adult patients: A cross-sectional study. J Glob Antimicrob Resist. 2020;20:43–49.
   PubMed Web of Science ®Google Scholar
• Batirel A, Balkan II, Karabay O, et al. Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections. Eur J Clin Microbiol Infect Dis. 2014;33:1311–1322.
   PubMed Web of Science ®Google Scholar
• Jung SY, Lee SH, Lee SY, et al. Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii pneumonia in critically ill patients: a systemic review and Bayesian network meta-analysis. Crit Care. 2017;21:319.
   PubMed Web of Science ®Google Scholar
• Rigatto MH, Vieira FJ, Antochevis LC, et al. Polymyxin B in combination with antimicrobials lacking in vitro activity versus Polymyxin B in monotherapy in critically Ill Patients with Acinetobacter baumannii or Pseudomonas aeruginosa infections. Antimicrob Agents Chemother. 2015;59:6575–6580.
   PubMed Web of Science ®Google Scholar
• Koch-Weser J, Sidel VW, Federman EB, et al. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med. 1970;72:857–868.
   PubMedGoogle Scholar
• Yahav D, Farbman L, Leibovici L, et al. Colistin: new lessons on an old antibiotic. Clin Microbiol Infect. 2012;18:18–29.
   PubMed Web of Science ®Google Scholar
• Durante-Mangoni E, Signoriello G, Andini R, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis. 2013;57:349–358.
   PubMed Web of Science ®Google Scholar
• Petrosillo N, Ioannidou E, Falagas ME. Colistin monotherapy vs combination therapy: evidence from microbiological, animal and clinical studies. Clin Microbiol Infect. 2008;14:816–827.
   PubMed Web of Science ®Google Scholar
• Cheah SE, Wang J, Nguyen VT, et al. New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection. J Antimicrob Chemother. 2015;70:3291–3297.
   PubMed Web of Science ®Google Scholar
• Garonzik SM, Li J, Thamlikitkul V, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother. 2011;55:3284–3294.
   PubMed Web of Science ®Google Scholar
• Karaiskos I, Friberg LE, Pontikis K, et al. Colistin population pharmacokinetics after application of a loading dose of 9 MU colistin methanesulfonate in critically Ill patients. Antimicrob Agents Chemother. 2015;59:7240–7248.
   PubMed Web of Science ®Google Scholar
• Nation RL, Garonzik SM, Thamlikitkul V, et al. Dosing guidance for intravenous colistin in critically-ill patients. Clin Infect Dis. 2017;64:565–571.
   PubMed Web of Science ®Google Scholar
• Paul M, Daikos GL, Durante-Mangoni E, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018;18:391–400.
   PubMed Web of Science ®Google Scholar
• Perazella MA. Drug-induced acute kidney injury: diverse mechanisms of tubular injury. Curr Opin Crit Care. 2019;25:550–557.
   PubMed Web of Science ®Google Scholar
• Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American thoracic society. Clin Infect Dis. 2016;63:e61–e111.
   PubMed Web of Science ®Google Scholar
• Rello J, Sole-Lleonart C, Rouby JJ, et al. Use of nebulized antimicrobials for the treatment of respiratory infections in invasively mechanically ventilated adults: a position paper from the European society of clinical microbiology and infectious diseases. Clin Microbiol Infect. 2017;23:629–639.
   PubMed Web of Science ®Google Scholar
• Fragkou PC, Poulakou G, Blizou A, et al. The role of minocycline in the treatment of nosocomial infections caused by multidrug, extensively drug and pandrug resistant Acinetobacter baumannii: a systematic review of clinical evidence. Microorganisms. 2019;7:159.
   Web of Science ®Google Scholar
• Ni W, Han Y, Zhao J, et al. Tigecycline treatment experience against multidrug-resistant Acinetobacter baumannii infections: a systematic review and meta-analysis. Int J Antimicrob Agents. 2016;47:107–116.
   PubMed Web of Science ®Google Scholar
• De Pascale G, Montini L, Pennisi M, et al. High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Crit Care. 2014;18:R90.
   PubMed Web of Science ®Google Scholar
• Garnacho-Montero J, Ferrandiz-Millon C. High dose of tigecycline for extremely resistant gram-negative pneumonia: yes, we can. Crit Care. 2014;18:157.
   PubMed Web of Science ®Google Scholar
• Wu X, Zhu Y, Chen Q, et al. Tigecycline therapy for nosocomial pneumonia due to carbapenem-resistant gram-negative bacteria in critically Ill patients who received inappropriate initial antibiotic treatment: a retrospective case study. Biomed Res Int. 2016;2016:8395268.
   PubMed Web of Science ®Google Scholar
• Busey K, Ferreira J, Aldridge P, et al. Treatment efficacy of Ampicillin/Sulbactam in comparison to alternative beta-lactams for severe Acinetobacter baumannii infections. Infect Dis (Lond). 2016;48:775–777.
   PubMed Web of Science ®Google Scholar
• Hiraki Y, Yoshida M, Masuda Y, et al. Successful treatment of skin and soft tissue infection due to carbapenem-resistant Acinetobacter baumannii by ampicillin-sulbactam and meropenem combination therapy. Int J Infect Dis. 2013;17:e1234–1236.
   PubMed Web of Science ®Google Scholar
• Lin HS, Lee MH, Cheng CW, et al. Sulbactam treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex. Infect Dis (Lond). 2015;47:370–378.
   PubMed Web of Science ®Google Scholar
• Oliveira MS, Costa SF, Pedri E, et al. The minimal inhibitory concentration for sulbactam was not associated with the outcome of infections caused by carbapenem-resistant Acinetobacter sp. treated with ampicillin/sulbactam. Clinics (Sao Paulo). 2013;68:569–573.
   PubMed Web of Science ®Google Scholar
• Oliveira MS, Prado GV, Costa SF, et al. Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother. 2008;61:1369–1375.
   PubMed Web of Science ®Google Scholar
• Ye JJ, Lin HS, Yeh CF, et al. Tigecycline-based versus sulbactam-based treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex. BMC Infect Dis. 2016;16:374.
   PubMed Web of Science ®Google Scholar
• Kengkla K, Kongpakwattana K, Saokaew S, et al. Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis. J Antimicrob Chemother. 2018;73:22–32.
   PubMed Web of Science ®Google Scholar
• Yamano Y. In vitro activity of cefiderocol against a broad range of clinically important gram-negative bacteria. Clin Infect Dis. 2019;69:S544–S551.
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Golden AR, Zelenitsky S, et al. Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant gram-negative Bacilli. Drugs. 2019;79:271–289.
   PubMed Web of Science ®Google Scholar
• Mollmann U, Heinisch L, Bauernfeind A, et al. Siderophores as drug delivery agents: application of the “Trojan Horse” strategy. Biometals. 2009;22:615–624.
   PubMed Web of Science ®Google Scholar
• Page MGP. The role of iron and siderophores in infection, and the development of siderophore antibiotics. Clin Infect Dis. 2019;69:S529–S537.
   PubMed Web of Science ®Google Scholar
• Wright H, Bonomo RA, Paterson DL. New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn? Clin Microbiol Infect. 2017;23:704–712.
   PubMed Web of Science ®Google Scholar
• Kazmierczak KM, Tsuji M, Wise MG, et al. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-beta-lactamase-producing isolates (SIDERO-WT-2014 Study). Int J Antimicrob Agents. 2019;53:177–184.
   PubMed Web of Science ®Google Scholar
• Hackel MA, Tsuji M, Yamano Y, et al. In Vitro activity of the siderophore cephalosporin, cefiderocol, against a recent collection of clinically relevant gram-negative Bacilli from North America and Europe, including carbapenem-nonsusceptible isolates (SIDERO-WT-2014 STUDY). Antimicrob Agents Chemother. 2017;61:e00093-17.
   Web of Science ®Google Scholar
• Hsueh SC, Lee YJ, Huang YT, et al. In vitro activities of cefiderocol, ceftolozane/ tazobactam,ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan. J Antimicrob Chemother. 2019;74:380–386.
   PubMed Web of Science ®Google Scholar
• Ito-Horiyama T, Ishii Y, Ito A, et al. Stability of novel siderophore cephalosporin S-649266 against clinically relevant carbapenemases. Antimicrob Agents Chemother. 2016;60:4384–4386.
   PubMed Web of Science ®Google Scholar
• Kohira N, West J, Ito A, et al. In vitro antimicrobial activity of a siderophore cephalosporin, S-649266, against enterobacteriaceae clinical isolates, including carbapenem-resistant strains. Antimicrob Agents Chemother. 2016;60:729–734.
   PubMed Web of Science ®Google Scholar
• Wu JY, Srinivas P, Pogue JM. Cefiderocol: a novel agent for the management of multidrug-resistant gram-negative organisms. Infect Dis Ther. 2020;9:17–40.
   PubMed Web of Science ®Google Scholar
• Portsmouth S, van Veenhuyzen D, Echols R, et al. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2018;18:1319–1328.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Giacobbe DR, Peghin M, et al. A look at clinical trial design for new antimicrobials for the adult population. Expert Rev Clin Pharmacol. 2019;12:1037–1046.
   PubMed Web of Science ®Google Scholar
• Wunderink RG, Matsunaga Y, Ari M, et al. LB4. efficacy and safety of cefiderocol vs. high-dose meropenem in patients with nosocomial pneumonia—results of a phase 3, randomized, multicenter, double-blind, non-inferiority study. Open Forum Infect Dis. 2019;6:S994–S994.
   Google Scholar
• Matsunaga Y, Echols R, Katsube T et al. Cefiderocol (S-649266) for Nosocomial Pneumonia Caused by Gram-Negative Pathogens: study Design of APEKS-NP, a Phase 3 Double-Blind Parallel-Group Randomized Clinical Trial. In: B42. CRITICAL CARE: THE FEVER - INFECTIONS IN THE ICU. American Thoracic Society; 2018. pp. A3290–A3290.
   Google Scholar
• Shionogi Inc. Briefing Information for the october 16, 2019 meeting of the antimicrobial drugs advisory committee [cited 2020 Jul 4]. Available from: https://www.fda.gov/media/131705/download.
   Google Scholar
• Shionogi Inc. FDA accepts shionogi’s supplemental new drug application with priority review for FETROJA® (cefiderocol) for the Treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia [cited 2020 Jul 4]. Available from: https://www.shionogi.com/us/en/news/2020/6/FDA-Accepts-Shionogis-Supplemental-New-Drug-Application-with-Priority-Review-for-FETROJA.html.
   Google Scholar
• Bassetti M, Ariyasu M, Binkowitz B, et al. Designing a pathogen-focused study to address the high unmet medical need represented by carbapenem-resistant gram-negative pathogens - the international, multicenter, randomized, open-label, phase 3 CREDIBLE-CR study. Infect Drug Resist. 2019;12:3607–3623.
   PubMed Web of Science ®Google Scholar
• Echols R, Ariyasu M, Nagata TD. Pathogen-focused clinical development to address unmet medical need: cefiderocol targeting carbapenem resistance. Clin Infect Dis. 2019;69:S559–S564.
   PubMed Web of Science ®Google Scholar
• EMA/CHMP/73102/2020. Committee for Medicinal Products for Human Use (CHMP). Summary of opinion (initial authorisation). Fetcroja (cefiderocol) [cited 2020 Jul 4]. Available from: https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-fetcroja_en.pdf.
   Google Scholar
• Fectroja. Summary of product characteristics [cited 2020 Jul 5]. Available from: https://www.ema.europa.eu/en/documents/product-information/fetcroja-epar-product-information_en.pdf.
   Google Scholar
• Bassetti M, Peghin M, Vena A, et al. Treatment of infections due to MDR gram-negative bacteria. Front Med (Lausanne). 2019;6:74.
   PubMed Web of Science ®Google Scholar
• Seifert H, Stefanik D, Sutcliffe JA, et al. In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii. Int J Antimicrob Agents. 2018;51:62–64.
   PubMed Web of Science ®Google Scholar
• Sutcliffe JA, O’Brien W, Fyfe C, et al. Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob Agents Chemother. 2013;57:5548–5558.
   PubMed Web of Science ®Google Scholar
• Solomkin J, Evans D, Slepavicius A, et al. Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the investigating gram-negative infections treated with eravacycline (IGNITE 1) trial: a randomized clinical trial. JAMA Surg. 2017;152:224–232.
   PubMed Web of Science ®Google Scholar
• Tetraphase Pharmaceuticals. Tetraphase announces top-line results from IGNITE3 phase 3 clinical trial of eravacycline in complicated urinary tract infections (cUTI) [cited 2020 Jul 4]. Available from: http://ir.tphase.com/news-releases/news-release-details/tetraphase-announces-top-line-results-ignite3-phase-3-clinical.
   Google Scholar
• Tetraphase Pharmaceuticals. Tetraphase announces top-line results from IGNITE2 phase 3 clinical trial of eravacycline in cUTI [cited 2020 Jul 4]. Available from: https://ir.tphase.com/news-releases/news-release-details/tetraphase-announces-top-line-results-ignite2-phase-3-clinical.
   Google Scholar
• Solomkin JS, Gardovskis J, Lawrence K, et al. IGNITE4: results of a phase 3, randomized, multicenter, prospective trial of eravacycline vs meropenem in the treatment of complicated intraabdominal infections. Clin Infect Dis. 2019;69:921–929.
   PubMed Web of Science ®Google Scholar
• Alosaimy S, Abdul-Mutakabbir JC, Kebriaei R, et al. Evaluation of eravacycline: a novel fluorocycline. Pharmacotherapy. 2020;40:221–238.
   PubMed Web of Science ®Google Scholar
• Wagenlehner FME, Cloutier DJ, Komirenko AS, et al. Once-daily plazomicin for complicated urinary tract infections. N Engl J Med. 2019;380:729–740.
   PubMed Web of Science ®Google Scholar
• Zemdri. Prescribing information. [cited 2020 Jul 4]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210303Orig1s000lbl.pdf.
   Google Scholar
• Garcia-Salguero C, Rodriguez-Avial I, Picazo JJ, et al. Can plazomicin alone or in combination be a therapeutic option against carbapenem-resistant Acinetobacter baumannii? Antimicrob Agents Chemother. 2015;59:5959–5966.
   PubMed Web of Science ®Google Scholar
• Landman D, Kelly P, Backer M, et al. Antimicrobial activity of a novel aminoglycoside, ACHN-490, against Acinetobacter baumannii and Pseudomonas aeruginosa from New York City. J Antimicrob Chemother. 2011;66:332–334.
   PubMed Web of Science ®Google Scholar
• Walkty A, Adam H, Baxter M, et al. In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011-2012. Antimicrob Agents Chemother. 2014;58:2554–2563.
   PubMed Web of Science ®Google Scholar
• Withdrawal letter: zemdri [cited 2020 Jul 4]. Available at: https://www.ema.europa.eu/documents/withdrawal-letter/withdrawal-letter-zemdri_en.pdf.
   Google Scholar
• Durand-Reville TF, Guler S, Comita-Prevoir J, et al. ETX2514 is a broad-spectrum beta-lactamase inhibitor for the treatment of drug-resistant gram-negative bacteria including Acinetobacter baumannii. Nat Microbiol. 2017;2:17104.
   PubMed Web of Science ®Google Scholar
• McLeod SM, Shapiro AB, Moussa SH, et al. Frequency and mechanism of spontaneous resistance to sulbactam combined with the novel beta-Lactamase Inhibitor ETX2514 in clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother. 2018;62:e01576-17.
   Web of Science ®Google Scholar
• Theuretzbacher U, Bush K, Harbarth S, et al. Critical analysis of antibacterial agents in clinical development. Nat Rev Microbiol. 2020;18:286–298.
   PubMed Web of Science ®Google Scholar
• Barnes MD, Kumar V, Bethel CR, et al. Targeting multidrug-resistant acinetobacter spp.: sulbactam and the diazabicyclooctenone beta-lactamase inhibitor ETX2514 as a novel therapeutic agent. mBio. 2019;10:e00159-19.
   Web of Science ®Google Scholar
• Penwell WF, Shapiro AB, Giacobbe RA, et al. Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii. Antimicrob Agents Chemother. 2015;59:1680–1689.
   PubMed Web of Science ®Google Scholar
• Brown P, Abbott E, Abdulle O, et al. Design of next generation polymyxins with lower toxicity: the discovery of SPR206. ACS Infect Dis. 2019;5:1645–1656.
   PubMed Web of Science ®Google Scholar
• Akhoundsadegh N, Belanger CR, Hancock REW. Outer membrane interaction kinetics of new polymyxin B analogs in gram-negative Bacilli. Antimicrob Agents Chemother. 2019;63:e00935-19.
   Web of Science ®Google Scholar
• Zhang Y, Zhao C, Wang Q, et al. Evaluation of the in vitro activity of new polymyxin B analogue SPR206 against clinical MDR, colistin-resistant and tigecycline-resistant Gram-negative bacilli. J Antimicrob Chemother. 2020;75(9):2609–2615.
   Web of Science ®Google Scholar
• Falagas ME, Skalidis T, Vardakas KZ, et al. Activity of TP-6076 against carbapenem-resistant Acinetobacter baumannii isolates collected from inpatients in Greek hospitals. Int J Antimicrob Agents. 2018;52:269–271.
   PubMed Web of Science ®Google Scholar
• Seifert H, Stefanik D, Olesky M, et al. In vitro activity of the novel fluorocycline TP-6076 against carbapenem-resistant Acinetobacter baumannii. Int J Antimicrob Agents. 2020;55:105829.
   PubMed Web of Science ®Google Scholar
• Lomovskaya O, Nelson K, Rubio-Aparicio D, et al. Impact of intrinsic resistance mechanisms on potency of QPX7728, a new ultrabroad-spectrum beta-lactamase inhibitor of serine and metallo-beta-lactamases in enterobacteriaceae, pseudomonas aeruginosa, and Acinetobacter baumannii. Antimicrob Agents Chemother. 2020;64:e00552-20.
   Web of Science ®Google Scholar
• Moya B, Barcelo IM, Bhagwat S, et al. Potent beta-lactam enhancer activity of zidebactam and WCK 5153 against Acinetobacter baumannii, including carbapenemase-producing clinical isolates. Antimicrob Agents Chemother. 2017;61:e01238-17.
   Web of Science ®Google Scholar
• Papp-Wallace KM, Nguyen NQ, Jacobs MR, et al. Strategic approaches to overcome resistance against gram-negative pathogens using beta-lactamase inhibitors and beta-lactam enhancers: activity of three novel diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234. J Med Chem. 2018;61:4067–4086.
   PubMed Web of Science ®Google Scholar
• World Health Organization. 2019 Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline [cited 2020 Jul 5]. Available from: https://apps.who.int/iris/bitstream/handle/10665/330420/9789240000193-eng.pdf.
   Google Scholar
• Wang L, Liu D, Lv Y, et al. Novel plasmid-mediated tet(X5) Gene conferring resistance to tigecycline, eravacycline, and omadacycline in a clinical Acinetobacter baumannii Isolate. Antimicrob Agents Chemother. 2019;64:e01326–19.
   PubMed Web of Science ®Google Scholar
• Shields RK, Iovleva A, Kline EG, et al. Clinical evolution of AmpC-mediated ceftazidime-avibactam and cefiderocol resistance in Enterobacter cloacae complex following exposure to cefepime. Clin Infect Dis. 2020. DOI:10.1093/cid/ciaa355.
   Web of Science ®Google Scholar